Abstract |
The epothilones represent a novel group of microtubule stabilization agents that appear to retain activity even in chemotherapy-resistant cell lines and animal models. Because of their ability to overcome chemotherapy resistance, we conducted a phase II study of Ixabepilone in patients with indolent non-Hodgkin lymphoma and mantle cell lymphoma (MCL). Ixabepilone was given at a dose of 25 mg/m(2) weekly for three of four consecutive weeks. Patients were required to have received < or =4 prior chemotherapy regimens, with an interval of at least one month since the last treatment, 3 months from prior rituximab, and 7 d from prior steroids, an absolute neutrophil count >1 x 10(9)/l and a platelet count >50 x 10(9)/l. Dose reductions were allowed. The overall response rate in assessable patients was 27% in this otherwise heavily treated population. One patient with chemotherapy-refractory follicular lymphoma attained a complete remission that lasted approximately 8 months. Three responses were also seen in refractory MCL and one in small lymphocytic lymphoma. The duration of response ranged from 2 to 8 months. Major toxicities included fatigue, myelosuppression and neuropathy. These data suggest that Ixabepilone has activity in chemotherapy-refractory lymphoma.
|
Authors | Owen A O'Connor, Carol Portlock, Craig Moskowitz, David Straus, Paul Hamlin, Michael Stubblefield, Otila Dumetrescu, A Dimitrios Colevas, Barbara Grant, Andrew Zelenetz |
Journal | British journal of haematology
(Br J Haematol)
Vol. 143
Issue 2
Pg. 201-9
(Oct 2008)
ISSN: 1365-2141 [Electronic] England |
PMID | 18691173
(Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents
- Epothilones
- ixabepilone
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents
(adverse effects, therapeutic use)
- Drug Administration Schedule
- Electromyography
- Epothilones
(adverse effects, therapeutic use)
- Female
- Humans
- Lymphoma, Follicular
(drug therapy)
- Lymphoma, Mantle-Cell
(drug therapy)
- Lymphoma, Non-Hodgkin
(drug therapy)
- Male
- Middle Aged
- Motor Neurons
- Neural Conduction
- Recurrence
- Remission Induction
- Sensory Receptor Cells
- Treatment Outcome
|